1. Home
  2. ASMB vs MDXH Comparison

ASMB vs MDXH Comparison

Compare ASMB & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • MDXH
  • Stock Information
  • Founded
  • ASMB 2005
  • MDXH 2003
  • Country
  • ASMB United States
  • MDXH Belgium
  • Employees
  • ASMB N/A
  • MDXH N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • MDXH
  • Sector
  • ASMB Health Care
  • MDXH
  • Exchange
  • ASMB Nasdaq
  • MDXH Nasdaq
  • Market Cap
  • ASMB 92.1M
  • MDXH 93.1M
  • IPO Year
  • ASMB 2010
  • MDXH 2021
  • Fundamental
  • Price
  • ASMB $13.21
  • MDXH $1.86
  • Analyst Decision
  • ASMB Buy
  • MDXH Strong Buy
  • Analyst Count
  • ASMB 2
  • MDXH 2
  • Target Price
  • ASMB $35.00
  • MDXH $7.00
  • AVG Volume (30 Days)
  • ASMB 22.3K
  • MDXH 113.8K
  • Earning Date
  • ASMB 03-27-2025
  • MDXH 02-26-2025
  • Dividend Yield
  • ASMB N/A
  • MDXH N/A
  • EPS Growth
  • ASMB N/A
  • MDXH N/A
  • EPS
  • ASMB N/A
  • MDXH N/A
  • Revenue
  • ASMB $28,326,000.00
  • MDXH $84,708,000.00
  • Revenue This Year
  • ASMB $282.16
  • MDXH $28.76
  • Revenue Next Year
  • ASMB N/A
  • MDXH $19.91
  • P/E Ratio
  • ASMB N/A
  • MDXH N/A
  • Revenue Growth
  • ASMB N/A
  • MDXH 33.01
  • 52 Week Low
  • ASMB $9.84
  • MDXH $1.55
  • 52 Week High
  • ASMB $19.93
  • MDXH $3.85
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 40.25
  • MDXH 33.28
  • Support Level
  • ASMB $13.60
  • MDXH $1.80
  • Resistance Level
  • ASMB $14.25
  • MDXH $1.97
  • Average True Range (ATR)
  • ASMB 0.58
  • MDXH 0.07
  • MACD
  • ASMB -0.05
  • MDXH -0.01
  • Stochastic Oscillator
  • ASMB 5.93
  • MDXH 12.50

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.

Share on Social Networks: